Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
On Demand Cases, Courses, and Papers
2019
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Updates from the Field
2019
Episode 157: March Retinal Physician Review with Dr. Shriji Patel including discussion of complement inhibition for AMD, faricimab, brolucizimab, and prefilled syringes for injectable medications
Jayanth Sridhar, MD
Member Podcasts
2018

Category: AMD-Neovascular

See more